Loading...
XNAS
AGPU
Market cap23mUSD
Jul 09, Last price  
6.97USD
1D
2.80%
1Q
75.13%
IPO
729.76%
Name

Predictive Oncology Inc

Chart & Performance

D1W1MN
XNAS:AGPU chart
P/E
P/S
188.79
EPS
Div Yield, %
Shrs. gr., 5y
96.33%
Rev. gr., 5y
-36.90%
Revenues
125k
-92.28%
015,73728896,637188,772468,125951,559654,354456,495654,8361,411,6551,411,5651,252,2721,420,6801,505,4591,627,6971,623,817125,284
Net income
-233m
L+1,810.42%
-1,762,628-2,892,230-1,352,709-4,486,879-7,422,155-9,406,304-6,833,568-4,790,530-6,526,014-6,003,017-10,086,477-19,390,766-25,884,397-19,657,174-25,737,634-13,983,967-12,201,261-233,095,203
CFO
-10m
L-16.70%
-900,528-1,309,985-820,680-1,781,631-1,184,165-3,855,166-3,371,413-7,487,293-4,381,440-4,459,750-5,287,956-8,732,451-12,257,732-12,208,929-12,370,800-13,189,391-11,955,671-9,958,577

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
IPO date
Dec 18, 2009
Employees
31
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT